Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Trial Profile

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 13 Mar 2017 Planned End Date changed from 1 Mar 2018 to 31 Mar 2019.
    • 13 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Mar 2018.
    • 04 May 2016 Planned End Date changed from 1 Mar 2019 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top